Welcome back to Endpoints Weekly! We unveiled our 2026 Women in Biopharma special project on Monday. Our team pored through nearly 200 nominations to reach this year’s list of 20 ...
Curium prices Bexlutry, its copycat of Novartis’ radioligand Lutathera, at $63,524 per infusion, about 5% below the original.
Pancreatic cancer patients with the most common KRAS mutation appeared to have a lower response rate than the overall patient ...
City Therapeutics eyes $158M IPO; Iambic Therapeutics targets $135M; Alchemist Capital launches with $100M; Life Biosciences ...
IPOs on Nasdaq, backed by Eli Lilly, focusing on Treg science for autoimmune disorders. Pipeline includes TRB-061 and a CD30 agonist for IBD.
PhRMA says FDA will get money it can spend only on hiring and keeping staff, to restore reviewer levels after the HHS layoffs ...
WHO releases preeclampsia roadmap; Comanche, DiaMedica, Avilar & ProFound developing treatments; Eli Lilly exploring the ...
Biohaven licenses pan-IgG degraders to Ono for $80M; UK pulls Ixchiq; ADC raises $86.6M; BMS Zenbexus Phase 3 win; Pfizer ...
Grindr acquires Freddie's parent for $250M to expand into HIV prevention (PrEP). The company will combine that with ED drugs and GLP-1s under new Grindr Health brand.
Petrelintide reduced patients’ average body weight by up to 9.2%, compared to 2.0% among those who received placebo.
General Medicine wants to be a one-stop shop for healthcare — whether it’s AI or a human doing the shopping. The one-stop shop is not a new concept. Many health tech companies, like Hims ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results